Inhouse product
Indications
Telukast is indicated
for:
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Pharmacology
Montelukast is a
selective and orally active leukotriene receptor antagonist that inhibits the
cysteinyl leukotriene receptor (CysLT1). The cysteinyl
leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released
from various cells, including mast cells and eosinophils. Cysteinyl
leukotrienes and leukotriene receptor occupation have been correlated with the
pathophysiology of asthma & allergic rhinitis, including airway edema,
smooth muscle contraction, and altered cellular activity associated with the
inflammatory process, which contribute to the signs and symptoms of asthma.
Dosage & Administration
Adults and adolescents
with asthma or seasonal allergic rhinitis:
Pediatric patients
with asthma or seasonal allergic rhinitis:
Use
in the pediatric patient:
The safety and efficacy of Montelukast have been established in adequate and
well-controlled studies in pediatric patients with asthma 6 months to 14 years
of age. Safety and efficacy profiles in this age group are similar to those
seen in adults.
Hepatic Insufficiency: No dosage adjustment is required in patients
with mild-to-moderate hepatic insufficiency.
Renal Insufficiency: No dosage adjustment is recommended in
patients with renal insufficiency.
Elderly use: The pharmacokinetic profile and the oral
bioavailability of a single 10-mg oral dose of montelukast are similar in
elderly and younger adults. The plasma half-life of montelukast is slightly
longer in the elderly. No dosage adjustment in the elderly is required.
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Interaction
Telukast has been
administered with other therapies routinely used in the prophylaxis and chronic
treatment of asthma with no apparent increase in adverse reactions. In drug
interaction studies, the recommended clinical dose of Telukast did not have
clinically important effects on the pharmacokinetics of the following drugs:
theophylline, prednisone, prednisolone, oral contraceptives (norethindrone
1mg/ethinyl estradiol 35mcg), terfenadine, digoxin, and warfarin. Although
additional specific interaction studies were not performed, Telukast was used
concomitantly with a wide range of commonly prescribed drugs in clinical
studies without evidence of clinical adverse interactions. These medications
included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory
agents, benzodiazepines and decongestants. Phenobarbital, which induces hepatic
metabolism, decreased the AUC of Telukast approximately 40% following a single
10mg dose of Telukast. No dosage adjustment for Telukast is recommended. It is reasonable
to employ appropriate clinical monitoring when potent cytochrome P450 enzyme
inducers, such as phenobarbital or rifampin, are co-administered with Telukast.
Contraindications
Montelukast is
contraindicated in patients who are hypersensitive to any component of this
product.
Side Effects
Common: Diarrhoea, fever, gastrointestinal
discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract
infection.
Uncommon: Akathisia, anxiety, arthralgia, asthenia,
abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage,
irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation,
sleep disorders.
Rare: Angioedema, concentration impaired,
disorientation, eosinophilic granulomatosis with polyangiitis, erythema
nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary
eosinophilia, suicidal tendencies, tremor.
Pregnancy & Lactation
Montelukast crosses
the placenta following oral dosing in rats and rabbits. There are, however, no
adequate and well-controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, Montelukast
should be used during pregnancy only if clearly needed. Because many drugs are
excreted in human milk, caution should be exercised when Montelukast is
given to a nursing mother.
Precautions & Warnings
Telukast is not
indicated for use in the reversal of bronchospasm in acute asthma attacks,
including status asthmaticus. Patients should be advised to have appropriate
rescue medication available. Therapy with Telukast can be continued during
acute exacerbations of asthma. While the dose of inhaled corticosteroid may be
reduced gradually under medical supervision, Telukast should not be abruptly
substituted for inhaled or oral corticosteroids. Telukast should not be used as
monotherapy for the treatment and management of exercise induced bronchospasm.
Patients with known aspirin sensitivity should continue avoidance of aspirin or
non-steroidal anti-inflammatory agents while taking Telukast. Although Telukast
is effective in improving airway function in asthmatics with documented aspirin
sensitivity, it has not been shown to truncate bronchoconstrictor response to
aspirin and other non-steroidal anti-inflammatory drugs in aspirin-sensitive
asthmatic patients.
Overdose Effects
There were no adverse
experiences in the majority of overdosage reports. The most frequently
occurring adverse experiences were consistent with the safety profile of
Telukast and included abdominal pain, somnolence, thirst, headache, vomiting
and psychomotor hyperactivity. In the event of overdose, it is reasonable to
employ the usual supportive measures; e.g., remove unabsorbed material from the
gastrointestinal tract, employ clinical monitoring, and institute supportive
therapy, if required.
Therapeutic Class
Leukotriene receptor
antagonists
Storage Conditions
Store in cool &
dry place below 30°C, protect from light & moisture. Keep out of reach of
children.
Chemical Structure
Molecular Formula : |
C35H36ClNO3S |
Chemical Structure : |
Common Questions about Telukast 4 mg Chewable
Tablet
What is Telukast 4 mg Chew. Tablet?
Telukast 4 mg Chew.
Tablet is a selective and orally active leukotriene receptor antagonist.
What is Telukast 4 mg Chew. Tablet used for?
Telukast 4 mg Chew.
Tablet is commonly used to treat asthma or allergic rhinitis. It helps keep
airways open and easy breathing by blocking leukotrienes.
How soon can the effect of Telukast 4 mg Chew.
Tablet be observed?
The effect of Telukast
4 mg Chew. Tablet can be observed after 1-3 hours of administration. Telukast 4
mg Chew. Tablet is not a fast-acting rescue medicine for asthma attacks and
needs to be taken daily to work properly.
How long does the effect of Telukast 4 mg
Chew. Tablet last?
The effect of Telukast
4 mg Chew. Tablet lasts for an average duration of 24 hours.
Should I use Telukast 4 mg Chew. Tablet empty
stomach?
Telukast 4 mg Chew.
Tablet may be taken with or without food as prescribed by your doctor.
What if I miss a dose of Telukast 4 mg Chew.
Tablet?
If you miss a dose,
you may take it as soon as possible. But if it is almost time for your next
dose, just skip that dose. Do not double up on doses.
Are there any pregnancy warnings for Telukast
4 mg Chew. Tablet?
Use of Telukast 4 mg
Chew. Tablet in pregnant women should be avoided unless clearly needed.
General Instructions
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Login Or Registerto submit your questions to seller
No none asked to seller yet